Login
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc.

edgewisetx.com

What Do They Do?

Develops small-molecule drug candidates for patients with muscular dystrophies and serious cardiac diseases.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ Turned profitable
vs −$40.7M in Q3 FY2025
  • Aug 6, 2026 Sold sevasemten and its muscular dystrophy business to Servier Servier acquired the program for $1.55 billion upfront, with up to $1.1 billion in additional milestone payments.

Broader clinical pipeline The older report described a lead clinical-stage candidate with other programs still preclinical; the latest describes multiple clinical-stage programs in muscular dystrophies and severe cardiac diseases, alongside preclinical programs.

Cardiometabolic focus The older report framed the preclinical discovery program as aimed at other cardiac disorders; the latest describes it as exploring candidates for cardiometabolic diseases.

Who Do They Compete With?

Competes with Sarepta Therapeutics, Nippon Shinyaku, Solid Biosciences, Genethon, Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Wave Life Sciences, Entrada Therapeutics, Vertex, PTC Therapeutics, Capricor Therapeutics, Satellos Bioscience, Bristol-Myers Squibb, Cytokinetics, Imbria Pharmaceuticals, Lexicon Pharmaceuticals, Celltrion, Braveheart Bio, and Pfizer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support